Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trial V118_05

NCT02255409 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT02255409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02255409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trial V118_05
Lead sponsor
Seqirus
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
January 31, 2016
Enrollment
607 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

influenza